World AMR Awareness Week (2/3): The empty pipeline
From 18 to 24 November, it is World AMR Awareness Week (WAAW). Under this year's theme, "One Health, one action: Prevent AMR now", we are publishing a series of three articles on antimicrobial resistance (AMR). In this second article, Gabriela Golda, PhD candidate at the Department of Medical Microbiology and Infection Prevention at Amsterdam UMC, explains why so few new antibiotics are being developed, what is needed to change that, and which alternatives to antibiotics are on the horizon.
Don't we still have enough antibiotics?
No, we actually don't. Although a few new antibiotics have been approved in recent years, truly new classes, especially against dangerous Gram-negative bacteria, have been very rare for several decades. Meanwhile, the antibiotics we do have are losing their effectiveness because of antimicrobial resistance. Bacteria can acquire mutations or resistance genes that let them survive drug treatment, for example by modifying the drug's target, breaking down the drug, or pumping it out of the cell. These resistant bacteria can then spread and transfer their resistance genes to other strains.
Why are so few new antibiotics being developed?
Mainly because it is not an attractive business model. Discovering and developing an antibiotic takes many years, followed by extensive safety and efficacy testing, and those costs are very high. Once a drug is on the market, patients take it only for a short period, days to weeks, unlike drugs for chronic diseases. New antibiotics are also kept as a last resort and used only when really needed, to slow resistance, which limits sales further. On top of that, every antibiotic carries the risk that resistance will emerge against it, shortening its useful lifetime.
As a result, early-stage discovery is mostly done at universities and small biotech companies, and a pharmaceutical company may step in once a promising candidate emerges. To change this, we need new payment models that reward companies for developing antibiotics regardless of how many are sold, together with more public funding for early-stage research.
What alternatives to antibiotics are being explored?
Phage therapy, using viruses that infect and kill bacteria, is one of the most promising approaches. It has been used routinely for decades in countries such as Georgia, although this experience largely predates modern clinical trials. In Europe (for example in Belgium) and the US, phages are mostly used case by case for patients with no other treatment options. Phages are much more specific than antibiotics, which means less harm to our gut bacteria. The challenge is that the right phage has to be matched to each infecting bacterium, and bacteria can evolve resistance to phages too. Phage therapy will therefore probably be a personalised treatment that is updated over time, and more clinical trials are needed to show how this can work in practice.
Other approaches include monoclonal antibodies, combination therapy (using more than one antibiotic), and synergistic approaches, in which compounds called adjuvants boost the activity of existing antibiotics.
What does your own research at Amsterdam UMC contribute?
In my research, I search for new helper compounds that can make existing antibiotics effective again. I test large collections of substances from nature, alongside synthetic, lab-made compounds. The compounds I am looking for make the outer wall of bacteria more permeable, so that an antibiotic can enter and do its work again. Combining an existing antibiotic with such a helper compound, a so-called adjuvant, one of the alternatives described above, can be faster and cheaper than developing a completely new antibiotic from scratch.
To test whether candidate compounds are safe and effective, I use zebrafish embryos. These tiny, transparent larvae allow us to follow an infection, and the effect of a treatment, in a living organism under the microscope. This allows us to filter out toxic or ineffective candidates at an early stage.
We recently used this model to characterize a new antibacterial compound, B1 (Cleenewerk, Golda et al., npj Antimicrobials and Resistance, 2026). In laboratory tests, B1 was active against a broad range of bacteria, including Mycobacterium tuberculosis, the bacterium that causes tuberculosis. In zebrafish embryos, B1 was well tolerated and cleared infections caused by two Gram-negative bacteria that are difficult to treat: Klebsiella pneumoniae and Acinetobacter baumannii.
How will the treatment of bacterial infections evolve over the next ten years?
In my opinion, treatment will become more targeted. Testing bacterial isolates for existing resistance will likely become routine in every medical laboratory, and I believe phages and monoclonal antibodies will find their place in the clinic. I also expect antibiotic use to be more closely monitored, both to prevent new resistance and to make sure patients complete their therapy, since stopping treatment too early is often a problem.
"I hope my work will contribute to making existing antibiotics effective again. I'm proud of how far this journey has taken me: as a researcher from Poland, the MSCA programme allowed me to move to Amsterdam, where I joined the Department of Medical Microbiology and Infection Prevention and learned new techniques such as working with zebrafish embryos. I also spent a few months at a company in Milan (NAICONS) to gain an industrial perspective. These experiences taught me to work in different environments and with scientists from around the world, and showed me how crucial collaboration and a multidisciplinary approach are. I'm excited about what the future holds, and I'm full of hope that new, effective treatments will be identified in the coming years."
Text: Gabriela Golda and Esmée Vesseur
This is the second article in a series of three. Yesterday we shared our article What is AMR? The silent pandemic, on Monday 23 November, we look at alternatives to antibiotics, as part of World AMR Awareness Week (WAAW, 18–24 November).